Mobile Game Developer King Acquires Artificial Intelligence Company Peltarion
King, a leading interactive entertainment company for the mobile gaming world, announced today the acquisition of artificial intelligence software company Peltarion.
Peltarion is a Swedish artificial intelligence (AI) software company and developer of a no-code, machine learning operations platform that empowers users to design, train and manage deep learning models in the Cloud at scale and at speed. King’s acquisition of Peltarion will accelerate the current use of AI and machine learning technology in King’s game platform, a key area of ongoing strategic direction for the company. With this investment, King aims to continue to build top-tier AI and machine learning capabilities and teams – enabling a new generation of innovative game design, development and live operations capabilities and becoming a hub for the world’s top talent in game AI.
“We are proud to announce the acquisition of Peltarion. Machine learning technology is moving quickly, and by increasing our investments in this field, we expect to deliver even more creative content to our 250 million monthly players* (Q1 2022) across the globe. We believe the talented Peltarion team, together with the powerful technology they have built, will help us serve our players even more effectively with more engaging games and content. This is yet another step towards our mission of making the world playful,” says Tjodolf Sommestad, President of King.
Founded in 2004 by Luka Crnkovic-Friis and Måns Essén, Peltarion is based in Stockholm and is one of Sweden’s most established AI innovators. Crnkovic-Friis and Essén will assume leadership roles at King, focusing on advancing King’s AI and machine learning capabilities and building on and contributing to Sweden’s AI community and rich history of innovation in this area.
“This is a monumental chapter in Peltarion history. We are excited to be part of a big AI success story in the Nordics, especially with Stockholm at its base. We are impressed with King for being one of the most successful Swedish tech companies and mobile game developers of modern time. The scale and reach of King, with iconic franchises like Candy Crush Saga, is a great match for our technology. The opportunities with AI seem to be endless, and we cannot wait to unlock the potential of working together,” said Luka Crnkovic-Friis, Peltarion CEO.
“It’s rare to find a team with such a depth of expertise in machine learning and AI technology combined with a long history of successfully delivering this capability to many different organizations in diverse domains and markets. We are privileged to be in a position to welcome the Peltarion team into the King family. We have an ambitious vision for the future of mobile games. Together with Luka, Måns, the team and their powerful AI platform, we’re accelerating our plan to use AI in how we create and operate our games to deliver this vision and to delight our players even more,” said Steve Collins, King Chief Technology Officer.
About King
King is a leading interactive entertainment company for the mobile world. It had 250 million monthly active users as of first quarter in 2022 across web, social and mobile platforms, and has developed more than 200 exclusive games that are enjoyed all around the world through its king.com, Facebook, and mobile distribution platforms such as the Apple App Store, Google Play Store, Microsoft Windows App Store and Amazon Appstore. King was acquired by Activision Blizzard (NASDAQ: ATVI) in 2016. King has game studios in Stockholm, Malmö, London, Barcelona and Berlin, along with offices in San Francisco, New York, and Malta.
About Peltarion
Peltarion is a leading Swedish AI innovator with its head office in Stockholm. The first platform “Synapse” was released in 2004, and helped companies and organizations like NASA, Tesla, Dell and Harvard to benefit from AI. The vision for Peltarion is to make AI accessible and affordable to more people and create a platform where people can work with AI without needing the skills of a data scientist is a step towards this vision. Among the Peltarion customers today, you will find enterprises in sectors ranging from manufacturing to retail. And the opportunities to do more expand every day.
Financial terms of this transaction were not disclosed.
*Monthly Active User (“MAU”): We monitor MAUs as a key measure of the overall size of our user base. MAUs are the number of individuals who accessed a particular game in a given month. We calculate average MAUs in a period by adding the total number of MAUs in each of the months in a given period and dividing that total by the number of months in the period. An individual who accesses two of our games would be counted as two users. In addition, due to technical limitations, an individual who accesses the same game on two platforms or devices in the relevant period would be counted as two users.
Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves King's expectations, plans, intentions or strategies regarding the Peltarion acquisition are forward-looking statements that are not facts and involve a number of risks and uncertainties. Factors that could cause King's actual future results to differ materially from those expressed in the forward-looking statements set forth in this release include unanticipated product delays and other factors identified in the risk factors sections of Activision Blizzard's most recent annual report on Form 10-K and any subsequent quarterly reports on Form 10-Q. The forward-looking statements in this release are based upon information available to King and Activision Blizzard as of the date of this release, and neither King nor Activision Blizzard assumes any obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of King or Activision Blizzard and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220613005280/en/
Contact information
FOR MEDIA ENQUIRIES: Press@king.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom